Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 15/20 | 0.71 |
| ▸ | PYGL | P06737 | 5/20 | 0.55 |
| ▸ | PYGM | P11217 | 5/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15957185 | 1.00 | RIPK1 (0.71) | RIPK1PYGLPYGM | |
| SCHEMBL15957163 | 0.88 | RIPK1 (0.59) | RIPK1PYGLPYGM | |
| SCHEMBL15956891 | 0.88 | RIPK1 (0.59) | RIPK1PYGLPYGM | |
| SCHEMBL17312719 | 0.88 | RIPK1 (0.57) | RIPK1PYGLPYGM | |
| SCHEMBL15957165 | 0.88 | RIPK1 (0.59) | RIPK1PYGLPYGM | |
| SCHEMBL17312721 | 0.88 | RIPK1 (0.57) | RIPK1PYGLPYGM | |
| SCHEMBL17312367 | 0.88 | RIPK1 (0.57) | RIPK1PYGLPYGM | |
| SCHEMBL17312798 | 0.88 | RIPK1 (0.59) | RIPK1PYGLPYGM | |
| SCHEMBL21307449 | 0.88 | RIPK1 (0.59) | RIPK1PYGLPYGM | |
| SCHEMBL17312370 | 0.88 | RIPK1 (0.57) | RIPK1PYGLPYGM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3508484-B1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2021-04-07 | — | — | EP | disclosed |
| US-10940154-B2 | Heterocyclic amides as kinase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-03-09 | — | — | US | disclosed |
| US-10933070-B2 | Heterocyclic amides as kinase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-03-02 | — | — | US | disclosed |
| EP-3342771-B1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-11-25 | — | — | EP | disclosed |
| EP-3375780-B1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-06-03 | — | — | EP | disclosed |
| WO-2020044206-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS FOR USE IN THE TREATMENT CANCER | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-03-05 | — | — | WO | disclosed |
| WO-2020044206-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS FOR USE IN THE TREATMENT CANCER | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-03-05 | — | — | WO | disclosed |
| US-20200062735-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-02-27 | — | — | US | disclosed |
| CN-110573504-A | heterocyclic amides as kinase inhibitors | 葛兰素史克知识产权开发有限公司 | 2019-12-13 | — | — | CN | disclosed |
| US-20190262356-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-08-29 | — | — | US | disclosed |
| US-20180098998-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-04-12 | — | — | US | disclosed |
| EP-2956452-B1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2018-03-21 | — | — | EP | disclosed |
| US-20170266199-A1 | HETEROCYCLIC AMIDES AS RIP1 KINASE INHIBITORS AS MEDICAMENTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-09-21 | — | — | US | disclosed |
| US-20170183332-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-06-29 | — | — | US | disclosed |
| US-9624202-B2 | Heterocyclic amides as kinase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-04-18 | — | — | US | disclosed |
| US-9556152-B2 | Heterocyclic amides as kinase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-01-31 | — | — | US | disclosed |
| US-20170008878-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-01-12 | — | — | US | disclosed |
| EP-2956452-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2015-12-23 | — | — | EP | disclosed |
| US-20150353533-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-12-10 | — | — | US | disclosed |
| WO-2014125444-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170183332-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | CNKSR1, ARAF, MAP4K2 | RIPK1 387/4885PYGL 1731/4885PYGM 2696/4885 |
| US-10940154-B2 | Heterocyclic amides as kinase inhibitors | CNKSR1, ARAF, MAP4K2 | RIPK1 387/4885PYGL 1731/4885PYGM 2696/4885 |
| US-20190262356-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | CNKSR1, ARAF, MAP4K2 | RIPK1 387/4885PYGL 1731/4885PYGM 2696/4885 |
| US-20170008878-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | CNKSR1, ARAF, MAP4K2 | RIPK1 387/4885PYGL 1731/4885PYGM 2696/4885 |
| US-20170266199-A1 | HETEROCYCLIC AMIDES AS RIP1 KINASE INHIBITORS AS MEDICAMENTS | RIPK1, RIPK2, RIPK3 | RIPK1 1/4885PYGL 519/4885PYGM 1192/4885 |
| US-20200062735-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | RIPK1, RIPK4, RIPK3 | RIPK1 1/4885PYGL 2632/4885PYGM 3671/4885 |
| US-20180098998-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | CNKSR1, ARAF, MAP4K2 | RIPK1 387/4885PYGL 1731/4885PYGM 2696/4885 |
| US-10933070-B2 | Heterocyclic amides as kinase inhibitors | CNKSR1, ARAF, MAP4K2 | RIPK1 387/4885PYGL 1731/4885PYGM 2696/4885 |
| US-20150353533-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | CNKSR1, ARAF, MAP3K3 | RIPK1 349/4885PYGL 1691/4885PYGM 2644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.